Poorly differentiated endocrine carcinoma of the pancreas responded to gemcitabine: Case report

World Journal of Gastroenterology

Volumn 16, Issue 30, 2010, Pages 3853-3856

  Nakazuru, Shoichi ^a   Yoshio, Toshiyuki ^a   Suemura, Shigeki ^a   Itoh, Mari ^a   Araki, Manabu ^a   Yoshioka, Chiaki ^a   Ohta, Makiyo ^a   Sueyoshi, Yuka ^a   Ohta, Takashi ^a   Hasegawa, Hiroko ^a   Morita, Kaori ^a   Toyama, Takashi ^a   Kuzushita, Noriyoshi ^a   Kodama, Yoshinori ^a   Mano, Masayuki ^a   Mita, Eiji ^a  

^a OSAKA NATIONAL HOSPITAL   (Japan)

Author keywords

Chemotherapy; Gemcitabine; Pancreatic endocrine tumor; Poorly differentiated endocrine carcinoma

Indexed keywords

CISPLATIN; ETOPOSIDE; GEMCITABINE; IRINOTECAN;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; ENDOCRINE TUMOR; FATIGUE; HUMAN; HUMAN TISSUE; ILEUS; INOPERABLE CANCER; MALE; MULTIPLE CYCLE TREATMENT; PANCREAS CARCINOMA; RARE DISEASE; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 77955751519     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i30.3853     Document Type: Article

References (21)

1. Moldow RE, Connelly RR. Epidemiology of pancreatic cancer in Connecticut. Gastroenterology 1968; 55: 677-686
2. Buchanan KD, Johnston CF, O'Hare MM, Ardill JE, Shaw C, Collins JS, Watson RG, Atkinson AB, Hadden DR, Kennedy TL, Sloan JM. Neuroendocrine tumors. A European view. Am J Med 1986; 81: 14-22
3. Eriksson B, Oberg K, Skogseid B. Neuroendocrine pancreatic tumors. Clinical findings in a prospective study of 84 patients. Acta Oncol 1989; 28: 373-377
4. Lam KY, Lo CY. Pancreatic endocrine tumour: a 22-year clinico-pathological experience with morphological, immunohistochemical observation and a review of the literature. Eur J Surg Oncol 1997; 23: 36-42
5. Lepage C, Bouvier AM, Phelip JM, Hatem C, Vernet C, Faivre J. Incidence and management of malignant digestive endocrine tumours in a well defined French population. Gut 2004; 53: 549-553
6. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072
7. Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer 1995; 75: 171-190
8. Bettini R, Boninsegna L, Mantovani W, Capelli P, Bassi C, Pederzoli P, Delle Fave GF, Panzuto F, Scarpa A, Falconi M. Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol 2008; 19: 903-908
9. Tomassetti P, Campana D, Piscitelli L, Casadei R, Santini D, Nori F, Morselli-Labate AM, Pezzilli R, Corinaldesi R. Endocrine pancreatic tumors: factors correlated with survival. Ann Oncol 2005; 16: 1806-1810
10. Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68: 227-232
11. Heitz PU, Komminoth P, Perren A, Klimstra DS, Dayal Y, Bordi C, Lechago J, Centeno BA, Klöppel G. Pancreatic endocrine tumours: Introduction. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C, editors. Pathology and Genetics, Tumours of Endocrine Organs. WHO Classification of Tumours. Lyon: IARC Press, 2004: 176-182
12. Fjällskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, Eriksson BK. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001; 92: 1101-1107
13. Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufié P, Aparicio T, Aparicio T, Lasser P, Elias D, Duvillard P, Schlumberger M, Rougier P. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999; 81: 1351-1355
14. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346: 85-91
15. Ansell SM, Pitot HC, Burch PA, Kvols LK, Mahoney MR, Rubin J. A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 2001; 91: 1543-1548
16. Ansell SM, Mahoney MR, Green EM, Rubin J. Topotecan in patients with advanced neuroendocrine tumors: a phase II study with significant hematologic toxicity. Am J Clin Oncol 2004; 27: 232-235
17. Kulke MH, Kim H, Clark JW, Enzinger PC, Lynch TJ, Morgan JA, Vincitore M, Michelini A, Fuchs CS. A Phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer 2004; 101: 934-939
18. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413
19. Cormier Y, Eisenhauer E, Muldal A, Gregg R, Ayoub J, Goss G, Stewart D, Tarasoff P, Wong D. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 1994; 5: 283-285
20. Masters GA, Declerck L, Blanke C, Sandler A, DeVore R, Miller K, Johnson D. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol 2003; 21: 1550-1555
21. van der Lee I, Smit EF, van Putten JW, Groen HJ, Schlösser NJ, Postmus PE, Schramel FM. Single-agent gemcitabine in patients with resistant small-cell lung cancer. Ann Oncol 2001; 12: 557-561